The U.S. Securities and Exchange Commission and U.S. Department of Justice have touted a renewed focus on traditional forms of securities fraud, including insider trading, accounting fraud and disclosure fraud involving public companies.
Government scrutiny and enforcement efforts have increasingly mounted against the life sciences and health care industry. Recent months have seen a wave of enforcement actions against publicly traded life sciences and health care companies and their executives involving allegations of insider trading or accounting fraud.
These actions underscore the need for public companies to implement internal controls for both accounting and trading activity to mitigate risk.
Source: SEC’s Life Sciences Actions Utilize Novel Tools and Theories | Morrison Foerster
